Drug profile · INN
gliclazide
APX-GLICLAZIDE
gliclazide (APX-GLICLAZIDE) is a sulfonylurea receptor 1, kir6.2 blocker. Associated with Servier Laboratories (Aust.) Pty..
TGA: approved
Patents linked 0
Pipeline programs 8
News articles 0
Drug details — gliclazide
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 8
- Data quality
- 0.81
Quick answer
gliclazide (APX-GLICLAZIDE) is a sulfonylurea receptor 1, kir6.2 blocker. Associated with Servier Laboratories (Aust.) Pty..
Key facts
INN gliclazide
Brand APX-GLICLAZIDE
Mechanism Sulfonylurea receptor 1, Kir6.2 blocker
Target Sulfonylurea receptor 1, Kir6.2
Originator Servier Laboratories (Aust.) Pty.
Mechanism of action
Sulfonylurea receptor 1, Kir6.2 blocker
Primary target: Sulfonylurea receptor 1, Kir6.2
Approval history
| Authority | Status | Date |
|---|---|---|
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is gliclazide?
gliclazide (APX-GLICLAZIDE) is a sulfonylurea receptor 1, kir6.2 blocker. Associated with Servier Laboratories (Aust.) Pty..
What is the brand name for gliclazide?
APX-GLICLAZIDE is a marketed brand name for gliclazide. Check FDA Drugs@FDA for the current US label holder and prescribing information.